1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
Barry Cohen
Barry Cohen
Articles (176) 

Translate Bio Boosted by Sanofi Vaccine Agreement

Stock price gains about 40% in 2 weeks

Sanofis (NASDAQ:SNY) decision to hedge its bet on developing a vaccine for Covid-19 has helped nearly double the year-to-date share price of a Boston-area therapeutics company.

Translate Bio Inc.s (NASDAQ:TBIO) partnership with Sanofi builds on the three-year pact the companies signed in June 2018 to use Translates technology called mRNA to develop vaccines for up to five infectious diseases. Given the worldwide pandemic, the Covid-19 vaccine is now front and center.

GENE News reported that Translate Bio CEO Ronald C. Renaud Jr. said the companies hope to begin animal testing in weeks. We have a goal to be in the clinic towards the end of this year, maybe the beginning of next year, but really driving toward the end of this year, he said. Thats all going to be subject to discussions with regulatory authorities. But were moving absolutely as quickly as we can.

Sanofi is also working on a vaccine with GlaxoSmithKline (NYSE:GSK). And along with other leading vaccine producers, the company is partnering with the U.S. governments Biomedical Advanced Research and Development Authority to select the Covid-19 strain sequence used in the design of the vaccine candidate.

Additionally, the French pharmaceutical giant is collaborating with Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to develop a new Covid-19 indication for the companies marketed arthritis drug Kevzara.


Translate Bio, formerly known as RaNa Therapeutics, was founded in 2011. The companys mRNA platform is a genetic technology intended to cajole the bodys cells into producing proteins that treat a disease or spark immunity to one.

Translates Covid-19 agreement is garnering all the attention, but the companys primary focus has been using its platform to develop treatments for pulmonary diseases like cystic fibrosis. The companys lead candidate for the disease is in clinical trials.

Under the 2018 agreement with Sanofi, Translate received $45 million upfront and could earn up to $760 million in potential milestones, according to an article in FiercePharma. Translate could also earn more from development, regulatory and sales milestones, or if Sanofi exercised options in additional disease areas. The company is also eligible for sales royalties if the programs make it to market.

In the first quarter, Translate posted a net loss of $14.3 million compared with $33.2 for the same period a year earlier. Revenue of $4.7 million, up $3.2 million from a year earlier, was derived from the Sanofi collaboration.

Translate stock closed May 8 at $14.50. According to CNN Money, the six analysts offering 12-month forecasts set a median target of $19.50, with a high estimate of $25 and a low of $17. The stock is rated a buy.

Disclosure: The author holds no positions in any of the stocks mentioned in this article.

Read more here:

Not a Premium Member of GuruFocus? Sign up for afree 7-day trial here.

About the author:

Barry Cohen
Barry Cohen has nearly 40 years experience in communications and marketing, the majority in senior positions at large international health care companies, including Abbott Laboratories and Bayer Inc.

He has contributed to a number of financial websites, writing primarily about the stocks of health care companies.

Rating: 0.0/5 (0 votes)


Please leave your comment:

Performances of the stocks mentioned by Barry Cohen

User Generated Screeners

pascal.van.garsseHigh FCF-M2
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)